Uptake Rates of Risk-Reducing Surgeries for Women at Increased Risk of Hereditary Breast and Ovarian Cancer Applied to Cost-Effectiveness Analyses: A Scoping Systematic Review

被引:9
作者
Galendi, Julia Simoes Correa [1 ]
Kautz-Freimuth, Sibylle
Stock, Stephanie
Mueller, Dirk [1 ]
机构
[1] Univ Cologne, Fac Med, Inst Hlth Econ & Clin Epidemiol, D-50935 Cologne, Germany
关键词
cost-effectiveness; patient-centered care; economic modeling; genetic testing; breast cancer; risk-reducing surgery; BRCA2; MUTATION; SALPINGO-OOPHORECTOMY; PROPHYLACTIC MASTECTOMY; PROSPECTIVE COHORT; PREVENTION; CARRIERS; ASSOCIATION; INFORMATION; TIME;
D O I
10.3390/cancers14071786
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary For women who have tested positive for BRCA mutations, the decision to make use of preventive surgical options, such as risk-reducing mastectomy (RRM) or risk-reducing bilateral salpingo-oophorectomy (RRSO), depends on the women's personal preferences and the cultural/social context. Among others, the cost-effectiveness of RRM and RRSO can be affected by the uptake rate of these preventive surgical options. Uptake rates of surgery should be given more attention in the conceptualization of health economic modeling studies for RRM and RRSO. Prospective multicenter studies are recommended to reflect regional and national variations in women's preferences for preventive surgery. The cost-effectiveness of genetic screen-and-treat strategies for women at increased risk for breast and ovarian cancer often depends on the women's willingness to make use of risk-reducing mastectomy (RRM) or salpingo-oophorectomy (RRSO). To explore the uptake rates of RRM and RRSO applied in health economic modeling studies and the impact of uptake rates on the incremental cost-effectiveness ratios (ICER), we conducted a scoping literature review. In addition, using our own model, we conducted a value of information (VOI) analysis. Among the 19 models included in the review, the uptake rates of RRM ranged from 6% to 47% (RRSO: 10% to 88%). Fifty-seven percent of the models applied retrospective data obtained from registries, hospital records, or questionnaires. According to the models' deterministic sensitivity analyses, there is a clear trend that a lower uptake rate increased the ICER and vice versa. Our VOI analysis showed high decision uncertainty associated with the uptake rates. In the future, uptake rates should be given more attention in the conceptualization of health economic modeling studies. Prospective studies are recommended to reflect regional and national variations in women's preferences for preventive surgery.
引用
收藏
页数:17
相关论文
共 70 条
[1]  
[Anonymous], DEV NICE NATL COLLAB
[2]  
Asphaug Lars, 2019, MDM Policy Pract, V4, p2381468318821103, DOI 10.1177/2381468318821103
[3]   Genetic counseling program in familial breast cancer:: Analysis of its effectiveness, cost and cost-effectiveness ratio [J].
Balmaña, J ;
Sanz, J ;
Bonfill, X ;
Casado, A ;
Rué, M ;
Gich, I ;
Díez, O ;
Sabaté, JM ;
Baiget, M ;
Alonso, MC .
INTERNATIONAL JOURNAL OF CANCER, 2004, 112 (04) :647-652
[4]  
Breheny N., COST EFFECTIVENESS P, DOI [10.1186/1746-5354-1-2-67.pdf, DOI 10.1186/1746-5354-1-2-67.PDF]
[5]   A Cost Decision Model Supporting Treatment Strategy Selection in BRCA1/2 Mutation Carriers in Breast Cancer [J].
Carbonara, Nunzia ;
La Forgia, Daniele ;
Pellegrino, Roberta ;
Ressa, Cosmo ;
Tommasi, Stefania .
JOURNAL OF PERSONALIZED MEDICINE, 2021, 11 (09)
[6]   Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers [J].
Chai, Xinglei ;
Friebel, Tara M. ;
Singer, Christian F. ;
Evans, D. Gareth ;
Lynch, Henry T. ;
Isaacs, Claudine ;
Garber, Judy E. ;
Neuhausen, Susan L. ;
Matloff, Ellen ;
Eeles, Rosalind ;
Tung, Nadine ;
Weitzel, Jeffrey N. ;
Couch, Fergus J. ;
Hulick, Peter J. ;
Ganz, Patricia A. ;
Daly, Mary B. ;
Olopade, Olufunmilayo I. ;
Tomlinson, Gail ;
Blum, Joanne L. ;
Domchek, Susan M. ;
Chen, Jinbo ;
Rebbeck, Timothy R. .
BREAST CANCER RESEARCH AND TREATMENT, 2014, 148 (02) :397-406
[7]   Preventing breast and ovarian cancers in high-risk BRCA1 and BRCA2 mutation carriers [J].
Collins, Ian M. ;
Milne, Roger L. ;
Weideman, Prue C. ;
McLachlan, Sue-Anne ;
Friedlander, Michael L. ;
Cuningham, Kathleen ;
Hopper, John L. ;
Phillips, Kelly-Anne .
MEDICAL JOURNAL OF AUSTRALIA, 2013, 199 (10) :680-683
[8]   NCCN Guidelines® Insights Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017 Featured Updates to the NCCN Guidelines [J].
Daly, Mary B. ;
Pilarski, Robert ;
Berry, Michael ;
Buys, Saundra S. ;
Farmer, Meagan ;
Friedman, Susan ;
Garber, Judy E. ;
Kauff, Noah D. ;
Khan, Seema ;
Klein, Catherine ;
Kohlmann, Wendy ;
Kurian, Allison ;
Litton, Jennifer K. ;
Madlensky, Lisa ;
Merajver, Sofia D. ;
Offit, Kenneth ;
Pal, Tuya ;
Reiser, Gwen ;
Shannon, Kristen Mahoney ;
Swisher, Elizabeth ;
Vinayak, Shaveta ;
Voian, Nicoleta C. ;
Weitzel, Jeffrey N. ;
Wick, Myra J. ;
Wiesner, Georgia L. ;
Dwyer, Mary ;
Darlow, Susan .
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2017, 15 (01) :9-19
[9]  
Ramos MCD, 2018, REV SAUDE PUBL, V52, DOI [10.11606/S1518-8787.2018052000643, 10.11606/s1518-8787.2018052000643]
[10]   Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers With Cancer Risk and Mortality [J].
Domchek, Susan M. ;
Friebel, Tara M. ;
Singer, Christian F. ;
Evans, D. Gareth ;
Lynch, Henry T. ;
Isaacs, Claudine ;
Garber, Judy E. ;
Neuhausen, Susan L. ;
Matloff, Ellen ;
Eeles, Rosalind ;
Pichert, Gabriella ;
Van T'veer, Laura ;
Tung, Nadine ;
Weitzel, Jeffrey N. ;
Couch, Fergus J. ;
Rubinstein, Wendy S. ;
Ganz, Patricia A. ;
Daly, Mary B. ;
Olopade, Olufunmilayo I. ;
Tomlinson, Gail ;
Schildkraut, Joellen ;
Blum, Joanne L. ;
Rebbeck, Timothy R. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2010, 304 (09) :967-975